Haemonetics (HAE) announces CSL has informed it of its intent not to renew its Supply Agreement

Go back to Haemonetics (HAE) announces CSL has informed it of its intent not to renew its Supply Agreement

Haemonetics (HAE) PT Lowered to $108 at Needham & Company; 'CSL Loss a Gut Punch But Not a Knock-Out'

April 19, 2021 12:06 PM EDT

Needham & Company analyst Mike Matson lowered the price target on Haemonetics (NYSE: HAE) to $108.00 (from $158.00) while maintaining a Buy rating after the company announced that CSL Plasma will not renew its supply agreement for the use of the PCS2 Plasma Collection System which expires on... More